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SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, 
ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the 
threshold of € 34,000 per QALY gained, that is twice the annual per capita income. 
The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at 
the threshold of € 34,000 per QALY gained was 100%. ConClusions: The results 
suggest that ranolazine as add–on treatment may be a cost-effective alterna-
tive for the symptomatic treatment of patients with chronic stable angina in 
Greece.
PCV123
Cost-Utility AnAlysis of APixAbAn in the ACUte treAtment And 
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objeCtives: To evaluate the cost-effectiveness of apixaban vs. existing thera-
peutic alternatives (fondaparinux/VKA, LMWH/VKA, rivaroxaban, dabigatran) 
in the acute treatment and prevention of venous thromboembolism (VTE) from 
the French National healthcare insurance perspective. Methods: A cohort of 
simulated patients with VTE were placed on one of five therapeutic strategies for 
6-months and tracked over a course of 5-years in a Markov model. Modeled clinical 
events included recurrent VTE, major bleed, clinically-relevant non-major bleed, 
chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome and 
death. Data on efficacy and safety were derived from a network meta-analysis. 
Medical costs of clinical events were extracted from a dedicated analysis of French 
health administrative databases and utility data were derived from literature. To 
assess the costs and benefits of extended treatment, treatment durations of 12 
and 18 months were examined in scenario analyses. Additionally, probabilistic 
sensitivity analyses that accounted for uncertainty in model parameters were 
conducted for each comparator. Results: Over treatment duration of 6 months 
at lifetime time horizon, apixaban was the dominant (less costly and more effec-
tive) alternative (6,573€ and 3.38 QALYs) compared to fondaparinux/VKA (6,621€ 
and 3.37 QALYs), LMWH/VKA (6,639€ and 3.37 QALYs), rivaroxaban (6,734€ and 3.38 
QALYs) and dabigatran (6,732€ and 3.37 QALYs). Probabilistic sensitivity analyses 
revealed apixaban was more likely to be cost-effective than all other strategies. 
Considering an extended treatment duration of 12 months, apixaban remained 
dominant versus rivaroxaban and dabigatran but cost-effective compared to fon-
daparinux/VKA (ICUR: 3,098€ /QALY) and LMWH/VKA (ICUR 2,381€ /QALY). Similar 
results were observed for treatment duration of 18 months with an increase of 
ICUR to 5,634€ /QALY and 5,083€ /QALY, respectively. ConClusions: Apixaban can 
offer substantial clinical and economic benefits over alternative therapies for 
acute and extended treatment of VTE.
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objeCtives: To conduct a systematic review on the pharmacoeconomic value of 
ranolazine vs standard-of-care (SOC) for the treatment of symptomatic chronic 
stable angina (CSA). Methods: Medline, Cochrane Library and Cost-Effectiveness 
Analysis Registry without time limits were searched. Articles in English were iden-
tified with the following keywords: cost, economic, ranolazine, ranexa, angina, 
coronary artery disease. The identified studies were independently reviewed by 
two investigators against pre-determined inclusion and exclusion criteria. The 
Quality of Health Economic Studies scale was used to assess the quality of the 
included studies. The data of selected studies were extracted onto a data extrac-
tion form and consequently were synthesized. Costing and effectiveness data for 
each comparator, incremental cost per quality-adjusted-life year (QALY) gained and 
results from sensitivity analyses were extracted. Results: Five studies containing 
evidence on effectiveness and cost of ranolazine were included in the review. Four 
of these studies assessed the cost–utility of ranolazine added to SOC compared to 
SOC alone, using decision tree or Markov models whereas one was a retrospective 
cost–comparative study. In all studies, patients were stratified according to their 
angina frequency symptoms. The analysis was conducted from a payer perspective 
in 4 studies and from the societal perspective in 1 study. The time horizon of analysis 
did not exceed the 1 year at any study. Ranolazine appeared to be cost-effective 
since it reduced the number of angina-related hospitalizations and improved qual-
ity of life with an Incremental Cost–Effectiveness Ratio (ICER) varying from € 4,000 
to € 15,000 per QALY gained. The ranolazine acquisition cost was the variable that 
mainly drove the ICER. ConClusions: The existing evidence showed that ranola-
zine is cost–effective for the second–line treatment of patients with symptomatic 
CSA, added to SOC. Further research is required to evaluate the cost – effectiveness 
of ranolazine in each angina frequency group.
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objeCtives: Cost-effectiveness analysis for secondary prevention with statins in 
Brazilian context are few and with efficacy data supported from primary RCT and 
utility values from foreign populations. Effectiveness from observational database 
and utility values from a similar population provides real world evidence. The aim of 
this study is to evaluate the cost-utility of secondary prevention with statins in fatal 
and non-fatal events based on real world data. Methods: A cohort markov model 
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objeCtives: This evaluation aimed to assess the cost-effectiveness of edoxaban 
60mg versus warfarin for the prevention of stroke and systemic embolic events 
among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the 
perspective of the NHS. Methods: A Markov model was developed to simulate 
the course of disease in hypothetical cohorts of patients with NVAF and to assess 
the cost-effectiveness of edoxaban versus the current UK standard of care, warfa-
rin. The model used data from the ENGAGE study, and was based on patients with 
CHADS2 ≥ 2. Utility values were derived from systematic literature reviews. Costs 
were extracted from the literature and the NHS reference cost database; both were 
discounted at 3.5% per annum. Health outcomes were assessed in quality-adjusted 
life years (QALYs), and evaluated over a lifetime time horizon. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to evaluate the effect of 
uncertainty in input parameters on the results. Results: In the base case analysis 
(CHADS2 ≥ 2), the incremental cost-effectiveness ratio (ICER) for edoxaban compared 
with warfarin was £12,881 per QALY gained. At a threshold of £20,000 per QALY, the 
net monetary benefit associated with edoxaban was £1,406. Edoxaban was also cost 
effective compared with warfarin in higher risk (CHADS2≥ 3) and higher anticoagu-
lant control (cTTR≥ 60%) subgroups (ICER £7,012 and £20,376 per QALY, respectively). 
Sensitivity analyses support these findings, and show that conclusions are robust to 
alternative assumptions about model inputs. Starting age, edoxaban cost, monitor-
ing costs and mortality due to non-ICH major bleeds are the drivers of the results. 
PSA indicates that 82% of simulations are in the north-east quadrant of the cost-
effectiveness plane for this comparison, and that the probability that edoxaban is 
cost-effective versus warfarin is more than 50%. ConClusions: Compared with 
warfarin, edoxaban represents a cost-effective alternative for stroke prevention in 
UK patients with NVAF.
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objeCtives: Randomized controlled trials have shown favorable effects of poly-
phenols and flavonoids found in chocolate on various cardiometabolic risk factors, 
including inflammatory markers, blood pressure, lipids, and insulin sensitivity. 
Epidemiologic studies also suggest chocolate may reduce risks of cardiometabolic 
diseases. This study aims to assess the cost-utility of chocolate consumption from 
a US health system perspective. Methods: A cohort life-table analysis was devel-
oped to model life years (LYs) and quality-adjusted life years (QALYs) of chocolate 
consumption versus non-consumption over a lifetime horizon in US adults. Age- 
and sex-specific disease incidence and mortality rates were used to model outcomes 
of cardiometabolic diseases, including coronary heart disease, stroke, and diabetes. 
Relative risks of cardiometabolic disease associated with chocolate consumption 
were obtained from meta-analyses of prospective cohort and cross-sectional stud-
ies. Utility weights, baseline healthcare costs, and attributable disease costs were 
obtained from the literature. Costs of chocolate were estimated based on “high” con-
sumption, consisting of three 150mg chocolate bars per week. Outcomes included 
undiscounted LYs and discounted costs and QALYs. Incremental analyses, strati-
fied by sex, and probabilistic sensitivity analyses (PSAs) were conducted. Results: 
Chocolate consumption, compared to none, increased undiscounted LYs by 0.74 
and 0.99 years and discounted QALYs by 0.54 and 0.45 years for males and females, 
respectively. Cardiometabolic disease costs were reduced by $7,763 and $6,318 and 
total healthcare costs were reduced by $5,660 and $2,717 for males and females, 
respectively. The incremental cost per QALY for chocolate consumption was $1,482 
for males and $8,931 for females. In the PSA chocolate consumption had a 97.8% 
and 89.9% probability of being cost-effective for males and females, respectively, at 
a $50,000/QALY threshold. ConClusions: Chocolate consumption may be a cost-
effective means to reduce the risk of cardiometabolic disease. Given the limitations 
of observational study data, further research is warranted to confirm these findings.
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objeCtives: To conduct an economic evaluation comparing ranolazine plus 
standard-of-care (SoC) relative to SoC alone, in patients with chronic stable angina 
who did not respond adequately to first line therapy, in Greece. Methods: A deci-
sion tree model was locally adapted in the Greek setting to evaluate the cost-utility 
of comparators during a 6-month period. The analysis was conducted from a payer 
(sickness fund) perspective. The clinical inputs were extracted from the published 
literature. The cost inputs considered reflect drug acquisition, hospitalizations, 
vascular interventions and monitoring of patients. Resource utilization data were 
obtained from 3 local experts. All costs refer to the year 2014. Cost-effectiveness 
was assessed by means of the incremental cost per quality adjusted life year 
(QALY) saved with the ranolazine as add-on therapy, relative to SoC alone (ICER). 
Probabilistic sensitivity analysis (PSA) was performed. Results: Ranolazine as 
add-on therapy was more costly compared to SoC alone, as the 6-month total cost 
per patient was € 1,170 and € 984, respectively. Patients received ranolazine plus 
